Close close

SEARCH

Enter your search term below:

WORLD LEADING BUSINESS SUPPORT

COMPANY A-Z

iQur Ltd

iQur is concentrating its therapeutic research and development on a vaccine platform based on exploiting the immune stimulant properties of Hepatitis B core. iQurÕs patented Tandem Core Technology (TCT) relies on the linkage of two HBV core molecules to form a stable backbone that combines to form virus like particles. Insertion of target antigens into the TCT produces a vaccine that combines the immune alert signal provided by the HBV core with targeting of the immune response to the inserted vaccine antigen. This technology can be used to generate immune responses against infectious pathogens including viruses, bacteria and parasites such and malaria, agents used in biodefence, anima pathogens and cancer associated antigens.

Close close

Mailing List sign-up

  • By submitting this form you agree to our privacy policy

LATEST
TWEETS

twitter twitter
Follow Us

SETsquared is a partnership between

  • University of Bath
  • University of Bristol
  • University of Exeter
  • University of Southampton
  • University of Surrey